Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00140517|
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : January 12, 2017
Plasmodium falciparum resistance to chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) continue to spread, impeding control of this important disease. CQ and SP are still the most commonly used antimalarial drugs for malaria prevention during pregnancy and might be made less effective by resistance. However, the treatment and prophylaxis regimens used may also create conditions for selecting resistant malaria parasite strains. A better understanding of the relationships between chemoprophylaxis regimens and resistance would be helpful to improve chemoprophylaxis of malaria in pregnancy.
This work aims to improve the use of chemoprophylaxis in pregnancy by determining whether there is a relationship between the use of standard prophylactic regimens with CQ and SP and the occurrence of P. falciparum resistant strains in pregnant women. The study consists of 2 parts. The first part is a randomized trial comparing 3 chemoprophylactic treatment groups: - weekly CQ after initial presumptive CQ treatment, - CQ intermittent presumptive treatment given as a standard dose at 2nd and 3rd trimester, respectively and SP intermittent presumptive treatment given as a single dose at 2nd and 3rd trimester, respectively. These treatment groups will also be compared to a group of women delivering at the same health centre but who have not been participating in the study. The second part will be a clinical trial for assessment of clinical and parasitological efficacy of CQ and SP treatment in pregnant women presenting with uncomplicated malaria attacks.
The study will be conducted from October 2002 to March 2005 in a health centre of Ouagadougou, Burkina Faso where malaria transmission is seasonal and resistance to CQ and SP is low.
|Condition or disease||Intervention/treatment||Phase|
|Malaria in Pregnancy Birth Weight Anaemia||Drug: sulphadoxine-pyrimethamine Drug: chloroquine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||700 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance|
|Study Start Date :||October 2002|
|Actual Primary Completion Date :||June 2007|
|Actual Study Completion Date :||March 2008|
- See detailed description
- see detailed description
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00140517
|Centre Medicale Paul VI|
|Ouagadougou, Burkina Faso, 01-2099|
|Principal Investigator:||Sheick O Coulibaly, MD||Laboratoire National de Sante Publique|